Conditions: Lung Cancer, Non-Small Cell
Keywords: EGFR ErbB1 ErbB2 metastatic lapatinib Her-2/neu protein kinase inhibitor BAC GW572016 Advanced NSCLC
Allocation: RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 131
Healthy volunteers: no

Brief summary:
This study was designed to evaluate and compare the efficacy of two dose schedules of an oral investigational drug for the treatment of advanced or metastatic non-small cell lung cancer.

Detailed description:

Arms:
arm 1: Randomized, open-label, parallel group, 2-stage study to evaluate and compare 2 dose schedules (1500 mg once daily and 500 mg twice daily) of oral lapatinib.

Interventions: intervention 1: GW572016 (lapatinib)
Intervention descriptions: intervention 1: tyrosine kinase inhibitor

Protocol document: